Skip to main content

Table 3 The predictors for virological suppression defined as HIV viral load < 400 copies/ml at week 48 of boosted protease inhibitor-based antiretroviral regimens

From: High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting

  Proportion of children with viral suppression n(%) Univariate analysis Multivariate analysis
   Odd Ratios (95%CI) P-value Odd Ratios (95%CI) P-value
ARV regimens      
 Single-boosted PI 54/65(83.1%) 1   1  
 Double-boosted PI 63/79 (79.8%) 0.80 (0.34-1.88) 0.611 0.82 (0.27-2.42) 0.712
Gender      
 Male 62/69 (89.9%) 3.22 (1.27-8.20) 0.014 2.85 (1.06-7.66) 0.018
 Female 55/75 (73.3%) 1   1  
Age, years      
 < 9.1 67/76 (88.2%) 2.68 (1.12-6.46) 0.028 3.60 (1.25-10.36) 0.038
 ≥ 9.1 50/68 (73.5%) 1   1  
Weight for age Z-score      
 < −1.7 42/59 (71.2%) 1   1  
 ≥ 1.7 64/72 (88.9%) 3.24 (1.28-8.18) 0.013 2.42 (0.85-6.84) 0.097
CD4 at time of switch to second line regimen      
 < 100 cell/mm3 30/42 (71.4%) 1   1  
 ≥100 cell/mm3 84/99 (84.9%) 2.24 (0.94-5.33) 0.068 2.12 (0.71-6.36) 0.178
Plasma HIV RNA at time of switch 
 < 4 log10 copies/ml 25/29 (86.2%) 1.53 (0.48-4.86)   - -
 ≥ 4 log10 copies/ml 25/111 (80.4%) 1 0.474   
Mono/dual NRTI exposure
 Yes 41/50 (82.0%) 1.08 (0.45-2.62) 0.867   
 No 76/94 (80.9%) 1    
Duration on NNRTI-based
 < 2.2 year 69/84(82.1%) 1.15 (0.50-2.67) 0.745   
 ≤ 2.2 year 48/60(80.0%) 1    
NNRTI –based regimen
 NVP-based 81/96 (84.4%) 1.80 (0.77-4.23) 0.178 1.24 (0.43-3.55) 0.691
 EFV-based 36/48 (75.0%) 1   1  
Multi-NRTI resistance    0.809 - -
 No TAMs 25/32 (78.1%) 1    
 Low grade multi-NRTI 35/44 (79.6%) 1.09 (0.36-3.31)    
 High grade multi-NRTI 36/43 (83.7%) 1.44 (0.45-4.62)    
LPV/r in the regimen
 Yes 60/71 (84.5%) 1.53 (0.66-3.58) 0.325   
 No 57/73 (78.1%) 1